{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:45Z","timestamp":1793140725214,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12035-021-02625-1","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:02:49Z","timestamp":1638432169000},"page":"1140-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson\u2019s Disease: Focus on Neuroinflammation"],"prefix":"10.1007","volume":"59","author":[{"given":"Bruno L.","family":"Santos-Lobato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Gustavo","family":"Gardinassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariza","family":"Bortolanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Ferranti","family":"Peti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngela V.","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facia Helena","family":"Faccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Del-Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-2709","authenticated-orcid":false,"given":"Vitor","family":"Tumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"2625_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"2625_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O et al (2005) Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord 20:224\u2013230","journal-title":"Mov Disord"},{"key":"2625_CR3","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner MC, Vogt T, Z\u00f6llner Y et al (2014) Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20:969\u2013974","journal-title":"Parkinsonism Relat Disord"},{"key":"2625_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/ene.13466","volume":"24","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Negre-Pages L, Damier P et al (2017) L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 24:1532\u20131538","journal-title":"Eur J Neurol"},{"key":"2625_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M Pechevis","year":"2005","unstructured":"Pechevis M, Clarke CE, Vieregge P et al (2005) Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study. European Journal of Neurology 12:956\u2013963","journal-title":"European Journal of Neurology"},{"key":"2625_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/mds.27783","volume":"34","author":"MJ Kelly","year":"2019","unstructured":"Kelly MJ, Lawton MA, Baig F et al (2019) Predictors of motor complications in early Parkinson\u2019s disease: a prospective cohort study. Mov Disord 34:1174\u20131183","journal-title":"Mov Disord"},{"key":"2625_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1590\/0004-282x20190191","volume":"78","author":"BL Santos-Lobato","year":"2020","unstructured":"Santos-Lobato BL, Schumacher-Schuh AF, Rieder CRM et al (2020) Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson\u2019s disease. Arq Neuropsiquiatr 78:206\u2013216","journal-title":"Arq Neuropsiquiatr"},{"key":"2625_CR8","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V et al (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106\u20131117","journal-title":"Lancet Neurol"},{"key":"2625_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/syn.21941","volume":"70","author":"E Del-Bel","year":"2016","unstructured":"Del-Bel E, Bortolanza M, Dos-Santos-Pereira M et al (2016) l-DOPA-induced dyskinesia in Parkinson\u2019s disease: are neuroinflammation and astrocytes key elements? Synapse 70:479\u2013500","journal-title":"Synapse"},{"key":"2625_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.nbd.2014.10.017","volume":"73","author":"M Bortolanza","year":"2015","unstructured":"Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE et al (2015) Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson\u2019s disease. Neurobiol Dis 73:377\u2013387","journal-title":"Neurobiol Dis"},{"key":"2625_CR11","doi-asserted-by":"publisher","first-page":"10.1098\/rstb.20","DOI":"10.1098\/rstb.2014.0190","volume":"370","author":"M Bortolanza","year":"2015","unstructured":"Bortolanza M, Padovan-Neto FE, Cavalcanti-Kiwiatkoski R et al (2015) Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson\u2019s disease induced by L-DOPA? Philos Trans R Soc Lond B Biol Sci 370:10.1098\/rstb.2014.0190","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2625_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","volume":"286","author":"G Mulas","year":"2016","unstructured":"Mulas G, Espa E, Fenu S et al (2016) Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson\u2019s disease. Exp Neurol 286:83\u201392","journal-title":"Exp Neurol"},{"key":"2625_CR13","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/brain\/awr165","volume":"134","author":"KE Ohlin","year":"2011","unstructured":"Ohlin KE, Francardo V, Lindgren HS et al (2011) Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134:2339\u20132357","journal-title":"Brain"},{"key":"2625_CR14","doi-asserted-by":"publisher","first-page":"16005","DOI":"10.1038\/s41598-017-16228-1","volume":"7","author":"RP Lerner","year":"2017","unstructured":"Lerner RP, Francardo V, Fujita K et al (2017) Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia. Sci Rep 7:16005","journal-title":"Sci Rep"},{"key":"2625_CR15","first-page":"85","volume-title":"Metabolomics in genetic testing","author":"J Troisi","year":"2020","unstructured":"Troisi J, Cavallo P, Colucci A et al (2020) Metabolomics in genetic testing. Advances in Clinical Chemistry. Elsevier, In, pp. 85\u2013153"},{"key":"2625_CR16","doi-asserted-by":"crossref","unstructured":"Stoessel D, Schulte C, dos Santos MCT et al (2018) Promising metabolite profiles in the plasma and CSF of early clinical Parkinson\u2019s disease. Frontiers in Aging Neuroscience 10","DOI":"10.3389\/fnagi.2018.00051"},{"key":"2625_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","volume":"14","author":"Y Shao","year":"2019","unstructured":"Shao Y, Le W (2019) Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease. Mol Neurodegener 14:3","journal-title":"Mol Neurodegener"},{"key":"2625_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnmol.2020.00080","volume":"13","author":"L Hu","year":"2020","unstructured":"Hu L, Dong M-X, Huang Y-L et al (2020) Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson\u2019s disease. Front Mol Neurosci 13:80","journal-title":"Front Mol Neurosci"},{"key":"2625_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147118","volume":"1748","author":"B Toczylowska","year":"2020","unstructured":"Toczylowska B, Zieminska E, Micha\u0142owska M et al (2020) Changes in the metabolic profiles of the serum and putamen in Parkinson\u2019s disease patients - in vitro and in vivo NMR spectroscopy studies. Brain Res 1748:147118","journal-title":"Brain Res"},{"key":"2625_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.135626","volume":"745","author":"M-X Dong","year":"2021","unstructured":"Dong M-X, Hu L, Wei Y-D, Chen G-H (2021) Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson\u2019s disease related anxiety disorder. Neuroscience Letters 745:135626","journal-title":"Neuroscience Letters"},{"key":"2625_CR21","doi-asserted-by":"crossref","unstructured":"Dong M-X, Wei Y-D, Hu L (2021) Lipid metabolic dysregulation is involved in Parkinson\u2019s disease dementia. Metabolic Brain Disease","DOI":"10.1007\/s11011-020-00665-5"},{"key":"2625_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.0000000000003663","volume":"88","author":"PA LeWitt","year":"2017","unstructured":"LeWitt PA, Li J, Lu M et al (2017) Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology 88:862\u2013869","journal-title":"Neurology"},{"key":"2625_CR23","doi-asserted-by":"publisher","first-page":"16690","DOI":"10.18632\/aging.103992","volume":"12","author":"SMS Yakhine-Diop","year":"2020","unstructured":"Yakhine-Diop SMS, Morales-Garc\u00eda JA, Niso-Santano M et al (2020) Metabolic alterations in plasma from patients with familial and idiopathic Parkinson\u2019s disease. Aging 12:16690\u201316708","journal-title":"Aging"},{"key":"2625_CR24","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"K-H Chang","year":"2018","unstructured":"Chang K-H, Cheng M-L, Tang H-Y et al (2018) Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson\u2019s disease. Mol Neurobiol 55:6319\u20136328","journal-title":"Mol Neurobiol"},{"key":"2625_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.14104","volume":"142","author":"JF Havelund","year":"2017","unstructured":"Havelund JF, Andersen AD, Binzer M et al (2017) Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem 142:756\u2013766","journal-title":"J Neurochem"},{"key":"2625_CR26","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22:1689\u2013707; quiz 1837","DOI":"10.1002\/mds.21507"},{"key":"2625_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/mds.26613","volume":"31","author":"UJ Kang","year":"2016","unstructured":"Kang UJ, Goldman JG, Alcalay RN et al (2016) The BioFIND study: characteristics of a clinically typical Parkinson\u2019s disease biomarker cohort. Mov Disord 31:924\u2013932","journal-title":"Mov Disord"},{"key":"2625_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170","journal-title":"Mov Disord"},{"key":"2625_CR29","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT (2008) The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 23:2398\u20132403","journal-title":"Mov Disord"},{"key":"2625_CR30","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00702-020-02240-9","volume":"127","author":"C Marchioni","year":"2020","unstructured":"Marchioni C, Santos-Lobato BL, Queiroz MEC et al (2020) Endocannabinoid levels in patients with Parkinson\u2019s disease with and without levodopa-induced dyskinesias. J Neural Transm 127:1359\u20131367","journal-title":"J Neural Transm"},{"key":"2625_CR31","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1007\/s00216-016-9445-8","volume":"408","author":"AF Galv\u00e3o","year":"2016","unstructured":"Galv\u00e3o AF, Petta T, Flamand N et al (2016) Plasma eicosanoid profiles determined by high-performance liquid chromatography coupled with tandem mass spectrometry in stimulated peripheral blood from healthy individuals and sickle cell anemia patients in treatment. Anal Bioanal Chem 408:3613\u20133623","journal-title":"Anal Bioanal Chem"},{"key":"2625_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00011-019-01297-x","volume":"69","author":"PAT Pereira","year":"2020","unstructured":"Pereira PAT, Bitencourt CS, Reis MB et al (2020) Immunomodulatory activity of hyaluronidase is associated with metabolic adaptations during acute inflammation. Inflamm Res 69:105\u2013113","journal-title":"Inflamm Res"},{"key":"2625_CR33","doi-asserted-by":"crossref","unstructured":"Yu T, Park Y, Johnson JM, Jones DP (2009) apLCMS--adaptive processing of high-resolution LC\/MS data. Bioinformatics 25:1930\u20131936","DOI":"10.1093\/bioinformatics\/btp291"},{"key":"2625_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003123","volume":"9","author":"S Li","year":"2013","unstructured":"Li S, Park Y, Duraisingham S et al (2013) Predicting network activity from high throughput metabolomics. PLoS Comput Biol 9:e1003123","journal-title":"PLoS Comput Biol"},{"key":"2625_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jms.4075","volume":"53","author":"APF Peti","year":"2018","unstructured":"Peti APF, Locachevic GA, Prado MKB et al (2018) High-resolution multiple reaction monitoring method for quantification of steroidal hormones in plasma. J Mass Spectrom 53:423\u2013431","journal-title":"J Mass Spectrom"},{"key":"2625_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbr.2018.03.020","volume":"347","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang G-J, Sun Y-N et al (2018) Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease by metabolomic technology. Behavioural Brain Research 347:175\u2013183","journal-title":"Behavioural Brain Research"},{"key":"2625_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12325-016-0474-7","volume":"34","author":"R Gualtierotti","year":"2017","unstructured":"Gualtierotti R, Guarnaccia L, Beretta M et al (2017) Modulation of neuroinflammation in the central nervous system: role of chemokines and sphingolipids. Adv Ther 34:396\u2013420","journal-title":"Adv Ther"},{"key":"2625_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-020-00408-1","volume":"15","author":"K Belarbi","year":"2020","unstructured":"Belarbi K, Cuvelier E, Bonte M-A et al (2020) Glycosphingolipids and neuroinflammation in Parkinson\u2019s disease. Mol Neurodegener 15:59","journal-title":"Mol Neurodegener"},{"key":"2625_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/biomedicines9050491","volume":"9","author":"J Fern\u00e1ndez-Irigoyen","year":"2021","unstructured":"Fern\u00e1ndez-Irigoyen J, Cartas-Cejudo P, Iruarrizaga-Lejarreta M et al (2021) Alteration in the cerebrospinal fluid lipidome in Parkinson\u2019s disease: a post-mortem pilot study. Biomedicines 9:491","journal-title":"Biomedicines"},{"key":"2625_CR40","doi-asserted-by":"crossref","unstructured":"Alessenko AV, Albi E (2020) Exploring sphingolipid implications in neurodegeneration. Frontiers in Neurology:11","DOI":"10.3389\/fneur.2020.00437"},{"key":"2625_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"H-J Kim","year":"2020","unstructured":"Kim H-J, Mason S, Foltynie T et al (2020) Motor complications in Parkinson\u2019s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 35:185\u2013190","journal-title":"Mov Disord"},{"key":"2625_CR42","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1016\/j.neurobiolaging.2015.08.027","volume":"36","author":"T Oeda","year":"2015","unstructured":"Oeda T, Umemura A, Mori Y et al (2015) Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson\u2019s disease. Neurobiol Aging 36:3306\u20133313","journal-title":"Neurobiol Aging"},{"key":"2625_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fneur.2020.00527","volume":"11","author":"DA Olszewska","year":"2020","unstructured":"Olszewska DA, McCarthy A, Soto-Beasley AI et al (2020) Association between glucocerebrosidase mutations and Parkinson\u2019s disease in Ireland. Front Neurol 11:527","journal-title":"Front Neurol"},{"key":"2625_CR44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K et al (2020) Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol 77:427\u2013434","journal-title":"JAMA Neurol"},{"key":"2625_CR45","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1345\/aph.1G271","volume":"39","author":"DQ Pham","year":"2005","unstructured":"Pham DQ, Plakogiannis R (2005) Vitamin E supplementation in Alzheimer\u2019s disease, Parkinson\u2019s disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother 39:2065\u20132072","journal-title":"Ann Pharmacother"},{"key":"2625_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3727\/096020198389960","volume":"11","author":"W-M Duan","year":"2002","unstructured":"Duan W-M, Rodrigues CMP, Zhao L-R et al (2002) Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson\u2019s disease. Cell Transplant 11:195\u2013205","journal-title":"Cell Transplant"},{"key":"2625_CR47","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1212\/WNL.0000000000001905","volume":"85","author":"H Mortiboys","year":"2015","unstructured":"Mortiboys H, Furmston R, Bronstad G et al (2015) UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo. Neurology 85:846\u2013852","journal-title":"Neurology"},{"key":"2625_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2019.01.003","volume":"96","author":"MO Mendes","year":"2019","unstructured":"Mendes MO, Rosa AI, Carvalho AN et al (2019) Neurotoxic effects of MPTP on mouse cerebral cortex: modulation of neuroinflammation as a neuroprotective strategy. Mol Cell Neurosci 96:1\u20139","journal-title":"Mol Cell Neurosci"},{"key":"2625_CR49","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","volume":"15","author":"S MahmoudianDehkordi","year":"2019","unstructured":"MahmoudianDehkordi S, Arnold M, Kwangsik N et al (2019) Altered bile acid profile associates with cognitive impairment in Alzheimer\u2019s disease \u2013 an emerging role for gut microbiome. Alzheimers Dement 15:76\u201392","journal-title":"Alzheimers Dement"},{"key":"2625_CR50","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.7150\/ijbs.44774","volume":"16","author":"A Kumari","year":"2020","unstructured":"Kumari A, Pal Pathak D, Asthana S (2020) Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism. Int J Biol Sci 16:2308\u20132322","journal-title":"Int J Biol Sci"},{"key":"2625_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jchromb.2018.01.025","volume":"1081-1082","author":"H Zhao","year":"2018","unstructured":"Zhao H, Wang C, Zhao N et al (2018) Potential biomarkers of Parkinson\u2019s disease revealed by plasma metabolic profiling. J Chromatogr B Analyt Technol Biomed Life Sci 1081-1082:101\u2013108","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2625_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao Y, Li T, Liu Z et al (2021) Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol Neurodegener 16:4","journal-title":"Mol Neurodegener"},{"key":"2625_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2019.109436","volume":"134","author":"Y Hasuike","year":"2020","unstructured":"Hasuike Y, Endo T, Koroyasu M et al (2020) Bile acid abnormality induced by intestinal dysbiosis might explain lipid metabolism in Parkinson\u2019s disease. Med Hypotheses 134:109436","journal-title":"Med Hypotheses"},{"key":"2625_CR54","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan AH, Chong CW, Lim SY et al (2021) Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol 89:546\u2013559","journal-title":"Ann Neurol"},{"key":"2625_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells8010027","volume":"8","author":"H Xicoy","year":"2019","unstructured":"Xicoy H, Wieringa B, Martens GJM (2019) The role of lipids in Parkinson\u2019s disease. Cells 8:27","journal-title":"Cells"},{"key":"2625_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuroscience.2008.07.016","volume":"156","author":"CJ Barnum","year":"2008","unstructured":"Barnum CJ, Eskow KL, Dupre K et al (2008) Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 156:30\u201341","journal-title":"Neuroscience"},{"key":"2625_CR57","doi-asserted-by":"crossref","unstructured":"Dos-Santos-Pereira M, da-Silva CA, Guimar\u00e3es FS, Del-Bel E (2016) Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 94:179\u2013195","DOI":"10.1016\/j.nbd.2016.06.013"},{"key":"2625_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104892","volume":"141","author":"I Espadas","year":"2020","unstructured":"Espadas I, Keifman E, Palomo-Garo C et al (2020) Beneficial effects of the phytocannabinoid \u0394-THCV in L-DOPA-induced dyskinesia in Parkinson\u2019s disease. Neurobiol Dis 141:104892","journal-title":"Neurobiol Dis"},{"key":"2625_CR59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.neuroscience.2009.01.034","volume":"159","author":"FE Padovan-Neto","year":"2009","unstructured":"Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009) Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson\u2019s disease. Neuroscience 159:927\u2013935","journal-title":"Neuroscience"},{"key":"2625_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neuropharm.2014.08.019","volume":"89","author":"FE Padovan-Neto","year":"2015","unstructured":"Padovan-Neto FE, Cavalcanti-Kiwiatkoviski R, Carolino ROG et al (2015) Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Neuropharmacology 89:87\u201399","journal-title":"Neuropharmacology"},{"key":"2625_CR61","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2014.09.010","volume":"73","author":"O Sol\u00eds","year":"2015","unstructured":"Sol\u00eds O, Espadas I, Del-Bel EA, Moratalla R (2015) Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-\/-) aphakia mice. Neurobiol Dis 73:49\u201359","journal-title":"Neurobiol Dis"},{"key":"2625_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","volume":"30","author":"M Bortolanza","year":"2016","unstructured":"Bortolanza M, Bariotto-Dos-Santos KD, Dos-Santos-Pereira M et al (2016) Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson\u2019s disease. Neurotox Res 30:88\u2013100","journal-title":"Neurotox Res"},{"key":"2625_CR63","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/mds.27799","volume":"34","author":"L Boi","year":"2019","unstructured":"Boi L, Pisanu A, Greig NH et al (2019) Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Mov Disord 34:1818\u20131830","journal-title":"Mov Disord"},{"key":"2625_CR64","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/bph.15439","volume":"178","author":"M Bortolanza","year":"2021","unstructured":"Bortolanza M, Nascimento GC, Raisman-Vozari R et al (2021) Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats. Br J Pharmacol 178:2595\u20132616","journal-title":"Br J Pharmacol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02625-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T09:57:02Z","timestamp":1676023022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02625-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2625"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02625-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.17.20233551","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ribeir\u00e3o Preto Medical School Ethics Committee (Number 3.036.243).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"VT received honoraria from Teva Brasil, UCB Biopharma, and Ipsen, and travel support for medical conferences from Roche.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}